Pharmacokinetics and pharmacodynamics of levodopa

被引:115
作者
Nutt, John G. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Neurol, Parkinson Dis Res Educ & Clin Ctr, Portland Va, OR 97239 USA
关键词
levodopa; short-duration response; motor fluctuations; dyskinesia;
D O I
10.1002/mds.22037
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The pharmacokinetics and pharmacodynamics of levodopa are dominated by two features: the Short plasma half-fife of the drug and the portion of the antiparkinsonian response that parallels the plasma levodopa levels. the so-called short-duration response. These features are the basis of Motor fluctuations that complicate long-term therapy with levodopa. Motor fluctuations will predictably improve with measures that prolong the elevations of plasma levodopa or prolong the efficacy of dopamine synthesized from exogenous levodopa. Because dyskinesia is closely linked to the short-duration response and conceivably part of the short-duration response, it is less clear that dyskinesia will be improved by therapeutic strategies that reduce motor fluctuations. (c) 2008 Movement Disorder Society.
引用
收藏
页码:S580 / S584
页数:5
相关论文
共 50 条
[41]   Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease [J].
Arabia, G ;
Zappia, M ;
Bosco, D ;
Crescibene, L ;
Bagalà, A ;
Bastone, L ;
Caracciolo, M ;
Scornaienghi, M ;
Quattrone, A .
NEUROLOGICAL SCIENCES, 2002, 23 (Suppl 2) :S53-S54
[42]   Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients [J].
Müller, T ;
Erdmann, C ;
Bremen, D ;
Schmidt, WE ;
Muhlack, S ;
Woitalla, D ;
Goetze, O .
CLINICAL NEUROPHARMACOLOGY, 2006, 29 (02) :61-67
[43]   Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects [J].
Almeida, Luis ;
Rocha, Jose Francisco ;
Falca, Amilcar ;
Nuno Palma, P. ;
Loureiro, Ana I. ;
Pinto, Roberto ;
Bonifacio, Maria Joao ;
Wright, Lyndon C. ;
Nunes, Teresa ;
Soares-da-Silva, Patricio .
CLINICAL PHARMACOKINETICS, 2013, 52 (02) :139-151
[44]   Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications [J].
Adamiak-Giera, Urszula ;
Jawien, Wojciech ;
Pierzchlinska, Anna ;
Bialecka, Monika ;
Kobierski, Jan Dariusz ;
Janus, Tomasz ;
Gawronska-Szklarz, Barbara .
PHARMACEUTICS, 2021, 13 (09)
[45]   Disease progression and pharmacodynamics in Parkinson disease - Evidence for functional protection with levodopa and other treatments [J].
Holford, Nicholas H. G. ;
Chan, Phylinda L. S. ;
Nutt, John G. ;
Kieburtz, Karl ;
Shoulson, Ira .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2006, 33 (03) :281-311
[46]   Levodopa-induced dyskinesias [J].
Fabbrini, Giovanni ;
Brotchie, Jonathan M. ;
Grandas, Francisco ;
Nomoto, Masahiro ;
Goetz, Christopher G. .
MOVEMENT DISORDERS, 2007, 22 (10) :1379-1389
[47]   Pharmacodynamics of levodopa coadministered with apomorphine in Parkinsonian patients with end-of-dose motor fluctuations [J].
Baas, H ;
Harder, S ;
Bürklin, F ;
Demisch, L ;
Fischer, PA .
CLINICAL NEUROPHARMACOLOGY, 1998, 21 (02) :86-92
[48]   Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments [J].
Nicholas H. G. Holford ;
Phylinda L. S. Chan ;
John G. Nutt ;
Karl Kieburtz ;
Ira Shoulson .
Journal of Pharmacokinetics and Pharmacodynamics, 2006, 33 :281-311
[49]   Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet®), sustained-release carbidopa-levodopa (Sinemet® CR), and carbidopa-levodopa-entacapone (Stalevo®) [J].
Hsu, Ann ;
Yao, Hsuan-Ming ;
Gupta, Suneel ;
Modi, Nishit B. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (09) :995-1003
[50]   Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa–Levodopa [J].
Aravind Mittur ;
Suneel Gupta ;
Nishit B. Modi .
Clinical Pharmacokinetics, 2017, 56 :999-1014